These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23359265)

  • 1. Comparison of nevirapine plasma concentrations between lead-in and steady-state periods in Chinese HIV-infected patients.
    Kou H; Du X; Li Y; Xie J; Qiu Z; Ye M; Fu Q; Han Y; Zhu Z; Li T
    PLoS One; 2013; 8(1):e52950. PubMed ID: 23359265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.
    van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Wit FW; Lange JM; Danner SA; Foudraine NA; Kwakkelstein MO; Reiss P; Beijnen JH; Hoetelmans RM
    AIDS; 2000 May; 14(8):F77-82. PubMed ID: 10853971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.
    Kappelhoff BS; Huitema AD; van Leth F; Robinson PA; MacGregor TR; Lange JM; Beijnen JH;
    HIV Clin Trials; 2005; 6(5):254-61. PubMed ID: 16306032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between nevirapine plasma concentrations and abnormal liver function tests.
    Almond LM; Boffito M; Hoggard PG; Bonora S; Raiteri R; Reynolds HE; Garazzino S; Sinicco A; Khoo SH; Back DJ; Di Perri G
    AIDS Res Hum Retroviruses; 2004 Jul; 20(7):716-22. PubMed ID: 15307917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.
    Baroncelli S; Villani P; Floridia M; Pirillo MF; Galluzzo CM; Cusato M; Amici R; Pinnetti C; Sabbatini F; Molinari A; Tamburrini E; Regazzi M
    Ther Drug Monit; 2008 Oct; 30(5):604-10. PubMed ID: 18728627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efavirenz and nevirapine plasma levels in HIV-infected patients with hemophilia].
    Martorell M; López RM; Ribera E; Ruiz I; Tural C; Puig L; Monterde J
    Enferm Infecc Microbiol Clin; 2005; 23(6):349-52. PubMed ID: 15970167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration.
    Ramachandran G; Hemanthkumar AK; Rajasekaran S; Padmapriyadarsini C; Narendran G; Sukumar B; Sathishnarayan S; Raja K; Kumaraswami V; Swaminathan S
    J Acquir Immune Defic Syndr; 2006 May; 42(1):36-41. PubMed ID: 16639340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nevirapine plasma concentrations are associated with virologic response and hepatotoxicity in Chinese patients with HIV infection.
    Wang J; Kou H; Fu Q; Han Y; Qiu Z; Zuo L; Li Y; Zhu Z; Ye M; Ma Q; Li T
    PLoS One; 2011; 6(10):e26739. PubMed ID: 22066007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia.
    Ellis JC; L'homme RF; Ewings FM; Mulenga V; Bell F; Chileshe R; Molyneux E; Abernethy J; van Oosterhout JJ; Chintu C; Walker AS; Gibb DM; Burger DM
    Antivir Ther; 2007; 12(2):253-60. PubMed ID: 17503667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.
    Kappelhoff BS; van Leth F; MacGregor TR; Lange J; Beijnen JH; Huitema AD;
    Antivir Ther; 2005; 10(1):145-55. PubMed ID: 15751772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations.
    De Requena DG; Jiménez-Nácher I; Soriano V
    AIDS Res Hum Retroviruses; 2005 Jun; 21(6):555-9. PubMed ID: 15989460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population.
    Mahungu T; Smith C; Turner F; Egan D; Youle M; Johnson M; Khoo S; Back Dj; Owen A
    HIV Med; 2009 May; 10(5):310-7. PubMed ID: 19228205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda.
    Penzak SR; Kabuye G; Mugyenyi P; Mbamanya F; Natarajan V; Alfaro RM; Kityo C; Formentini E; Masur H
    HIV Med; 2007 Mar; 8(2):86-91. PubMed ID: 17352764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing plasma nevirapine levels: a study in HIV-infected children on generic antiretroviral treatment in India.
    Swaminathan S; Ramachandran G; Agibothu Kupparam HK; Mahalingam V; Soundararajan L; Perumal Kannabiran B; Navaneethapandian PG; Shah I; Karunaianandham R; Sikhamani R
    J Antimicrob Chemother; 2011 Jun; 66(6):1354-9. PubMed ID: 21393201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical guidelines to interpret plasma concentrations of antiretroviral drugs.
    Leith J; Hinzmann R; Mayers D
    Clin Pharmacokinet; 2005; 44(4):439; author reply 439-40. PubMed ID: 15828857
    [No Abstract]   [Full Text] [Related]  

  • 16. Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.
    Moltó J; Valle M; Miranda C; Cedeño S; Miranda J; Santos JR; Negredo E; Vilaró J; Costa J; Clotet B
    J Antimicrob Chemother; 2008 Oct; 62(4):784-92. PubMed ID: 18593723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection.
    Yong CL; Gathe JC; Knecht G; Orrell C; Mallolas J; Podzamczer D; Trottier B; Zhang W; Sabo JP; Vinisko R; Drulak M; Quinson AM
    HIV Clin Trials; 2017; 18(5-6):189-195. PubMed ID: 29210627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population.
    de Vries-Sluijs TE; Dieleman JP; Arts D; Huitema AD; Beijnen JH; Schutten M; van der Ende ME
    Clin Pharmacokinet; 2003; 42(6):599-605. PubMed ID: 12793844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission.
    Jackson JB; Parsons T; Musoke P; Nakabiito C; Donnell D; Fleming T; Mirochnick M; Mofenson L; Fowler MG; Mmiro F; Guay L
    AIDS; 2006 Jan; 20(2):217-22. PubMed ID: 16511414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized controlled study.
    Parienti JJ; Massari V; Reliquet V; Chaillot F; Le Moal G; Arvieux C; Vabret A; Verdon R;
    AIDS; 2007 Oct; 21(16):2217-22. PubMed ID: 18090049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.